4.8 Article

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells

期刊

CANCER RESEARCH
卷 75, 期 14, 页码 2800-2810

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-14-3041

关键词

-

类别

资金

  1. NCI (National Cancer Institute) [P01 CA 66726-07, R01 CA169123, R21 CA169741, R01 CA141144, R01 CA 172921]
  2. Cancer Research Institute
  3. Novartis Pharmaceuticals Corporation
  4. Lung Cancer and Pancreatic Cancer Translational Centers of Excellence at the Abramson Cancer Center
  5. START (Student Training and Research in Tumor Immunology) fellowship from the Cancer Research Institute
  6. Pittsburgh 5K Cure Sarcoma Award

向作者/读者索取更多资源

Malignant cells drive the generation of a desmoplastic and immunosuppressive tumor microenvironment. Cancer-associated stromal cells (CASC) are a heterogeneous population that provides both negative and positive signals for tumor cell growth and metastasis. Fibroblast activation protein (FAP) is a marker of a major subset of CASCs in virtually all carcinomas. Clinically, FAP expression serves as an independent negative prognostic factor for multiple types of human malignancies. Prior studies established that depletion of FAP(+) cells inhibits tumor growth by augmenting antitumor immunity. However, the potential for immune-independent effects on tumor growth have not been defined. Herein, we demonstrate that FAP(+) CASCs are required for maintenance of the provisional tumor stroma because depletion of these cells, by adoptive transfer of FAP-targeted chimeric antigen receptor (CAR) T cells, reduced extracellular matrix proteins and glycosaminoglycans. Adoptive transfer of FAP-CAR T cells also decreased tumor vascular density and restrained growth of desmoplastic human lung cancer xenografts and syngeneic murine pancreatic cancers in an immune-independent fashion. Adoptive transfer of FAP-CAR T cells also restrained autochthonous pancreatic cancer growth. These data distinguish the function of FAP_ CASCs from other CASC subsets and provide support for further development of FAP_ stromal cell-targeted therapies for the treatment of solid tumors. (C) 2015 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据